Non-Small Cell Lung Cancer (NSCLC)
Conditions
Keywords
Non-Small Cell Lung Cancer (NSCLC), Anaplastic lymphoma kinase, ALK, Brain metastases
Brief summary
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
Detailed description
This is a Phase I/II clinical trial. * A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose(s) of the investigational intervention to use for further studies. * Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. * Investigational means that the intervention is being studied. * In this research study, the investigators are investigating the combination of two study drugs: alectinib and bevacizumab. The FDA (the U.S. Food and Drug Administration) has not approved alectinib as a treatment for any disease. It has been found that some people with NSCLC have a change (mutation) in a certain gene called the anaplastic lymphoma receptor tyrosine kinase (ALK) gene. This mutated gene helps cancer cells grow. \-- Alectinib belongs to a class of drugs designed to inhibit ALK. This drug has been used in other research studies. Information from those other research studies suggests that alectinib may be effective in killing cancer cells that have changes in ALK. Only participants with changes in the ALK gene will be allowed to participate in this study. In this research study, Alectinib will be combined with Bevacizumab. -- Bevacizumab (also called Avastin) works by slowing or stopping the growth of cells in cancer tumors by decreasing the blood supply of the tumors. If blood supply is decreased, oxygen and nutrients that are needed for tumor growth are decreased. The FDA has approved Bevacizumab as a treatment option for your disease The purpose of this study is to test the safety of Alectinib and Bevacizumab. The investigators will also determine how effective this combination is in participants with advanced, ALK-positive NSCLC with a focus on participants with brain metastases. In the phase I portion of the study, a 3 + 3 dose de-escalation design was to determine the recommended phase II dose (RP2D) of alectinib and bevacizumab. Three patients will be treated per cohort for one cycle (21 days per cycle) beginning with dose level 1 cohort. * Dose level 1 (starting dose) = Alectinib 600mg twice daily orally (PO), and Bevacizumab 15 mg/kg administered intravenously (IV) every 3 weeks. \-- Dose level 1 was selected based on the individual RP2Ds for each medication and anticipation for minimal overlapping toxicities. * Dose level -1 = Alectinib 600mg twice daily orally (PO),and Bevacizumab 7.5 mg/kg administered intravenously (IV) every 3 weeks. * Dose level -2 = Alectinib 450mg twice daily orally (PO), and Bevacizumab 7.5 mg/kg administered intravenously (IV) every 3 weeks. DLTs were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs, and grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. If no DLTs are observed with dose level 1 cohort, we will enroll an additional 3 participants (6 total) to the same cohort and proceed with the phase II portion of the study if one or less experience a DLT. In any other dose level cohort, if one of three patients experiences a DLT, another 3 patients will be treated at the same dose level for one cycle. If no additional DLTs are observed, we will proceed with the phase II portion of the trial. If more than one of 3 patients develops a DLT in any cohort, another 3 patients will be treated in the next lowest dose cohort. The RP2D for the combination of alectinib and bevacizumab was defined as either (i) the highest dosage cohort in which less than a third of patients experienced a DLT, or (ii) alectinib at the previously defined RP2D as a single agent (600 mg twice daily) plus bevacizumab at the highest tolerated dose investigated for the indication (15 mg/kg every 21 days), whichever was the lower dose. In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion. Cycles were 21 days long. Treatment was continued until there was evidence of progressive disease, death, or unacceptable toxicity. Patients were allowed to continue study drugs beyond progression if deemed clinically beneficial at the investigator's discretion. Intra-patient dose modification of bevacizumab was not permitted.
Interventions
DRUGAlectinib
DRUGBevacizumab
Sponsors
Genentech, Inc.
Massachusetts General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed advanced, non-squamous, non-small cell lung cancer. * Molecular confirmation of an ALK rearrangement. * Age ≥ 18 years old. * Life expectancy \> 12 weeks. * Performance status 0-2. * Adequate hematologic function: * Adequate renal function: * An estimated Glomerular Filtration Rate (eGFR) of at least 45 mL/min/1.73 m2 * International normalized ration (INR)≤ 1.5 * Partial thromboplastin time (PTT) ≤1.5 x upper limit of normal (ULN) * For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment. * Able and willing to provide written informed consent * Phase II Only: * Presence of at least one measurable central nervous system (CNS) target lesion (At least 5 mm in size) * Lesions must be untreated or progressive according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after previous local therapy. * Participants who are receiving corticosteroids must be on a stable or decreasing dose * At least one measurable extra-CNS lesion based upon RECIST version 1.1.
Exclusion criteria
* Squamous cell histology or mixed, predominantly squamous adenosquamous carcinoma * Previous history of haemoptysis * Tumour infiltrating into large vessels or infiltrating into the proximal tracheobronchial network * Unstable, symptomatic brain metastases. * History of hemorrhagic CNS metastases * History of intracranial hemorrhage (either by clinical history or neuroimaging) * History of or genetic predisposition to a bleeding diathesis or coagulopathy * Therapeutic anticoagulation * Current or recent (within 10 days of first dose of bevacizumab) use of aspirin (\> 325 mg/day) * Clinically significant heart disease (i.e., active), stroke or myocardial infarction within 6 months prior to enrolment, unstable angina pectoris, congestive heart failure of grade \> II according to the New York Heart Association (NYHA), or cardiac arrhythmia requiring specific treatment * Arterial or venous thromboembolic events within 6 months of study enrollment. * Poorly controlled arterial hypertension (systolic \> 150 mm Hg and/or diastolic \> 100 mm Hg) * Invasive surgical intervention within 28 days prior to the start of treatment * Minor surgical intervention, including placement of a permanent catheter within 24 hours prior to the first infusion of bevacizumab. * Non-healing wound, active peptic ulcer or bone fracture. * Previous history of abdominal fistula, tracheoesophageal fistula or other fistula with grade 4 severity, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to enrolment. * Proteinuria at baseline. * Previous anti-angiogenic treatment * Patients previously treated with alectinib (Phase II only). * Radical radiotherapy to the thorax with curative intent within 28 days * Cytotoxic chemotherapy within 21 days prior to enrolment. * Treatment with crizotinib within 7 days prior to enrolment. For all other ALK Tyrosine kinase inhibitors (TKIs), the washout period should be ≥5 half-lives prior to enrolment. * Any GI disorder that may affect absorption of oral medications * Alanine transaminase (ALT) or aspartate transaminase (AST) \> 3 × ULN (≥5 × ULN for patients with concurrent liver metastasis) * Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices * Acute viral or active autoimmune, alcoholic, or other types of hepatitis * National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g. radiotherapy) (excluding alopecia), * History of organ transplant. * Co-administration of anti-cancer therapies other than those administered in this study. * QTc \> 470 ms or patients with symptomatic bradycardia. * Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days * Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment. * History of hypersensitivity to any of the additives in the alectinib drug formulation * Documented allergy or hypersensitivity to monoclonal antibodies (bevacizumab) * History of drug-induced pneumonitis or hypersensitivity pneumonitis from prior ALK TKI therapy. * Pregnant or lactating women. * Known HIV positivity or AIDS-related illness. * Any condition or illness that could compromise patient safety or interfere with the evaluation of the study drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| (Phase 1) Recommended Phase II Dose of Alectinib | first cycle of treatment (21 days) | The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose. Dose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs. |
| (Phase 1) Recommended Phase II Dose of Bevacizumab | first cycle of treatment (21 days) | The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose. Dose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs. |
| (Phase 2) Number of Participants With Intracranial Hemorrhagic Events Who Received RP2D | up to 4 years | In the phase II portion of the study, we aim to further investigate the safety and tolerability of alectinib plus bevacizumab at the RP2Ds as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The combination of alectinib and bevacizumab will be deemed unsafe if 2 or more participants are observed to have grade 2 or higher, central nervous system (CNS) intracranial hemorrhagic events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Objective Response Rate | Up to 4 years | Objective response rate (ORR) is defined as the percentage of participants with intra- and extra-cranial complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. |
| Overall Disease Control Rate | Up to 4 years | Disease control rate (DCR) is the percentage of participants with intra- and extra-cranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1: * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. * SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters. * PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD. |
| Central Nervous System Disease Control Rate | Up to 4 years | Disease control rate (DCR) is the percentage of participants with intracranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response: * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. * SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters. * PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD. |
| Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline to cycle 7 (21 weeks) | The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of functional scales, symptom scales, a global health status/quality of life (QOL) scale. All of the scales range in score from 0 to 100. A summary score is calculated as the average of all scores. High score for functional scales mean high level of functioning. High score for global health status means high quality of life. High score for symptom scales mean high level of problems. |
| Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline, Cycle 7 Day 1 (21 weeks) | The European Organization for Research and Treatment of Cancer quality of life questionnaire has a brain cancer nodule (EORTC QLQ-BN20) developed for patients undergoing chemotherapy or radiotherapy. It includes 20 items, 13 of which aggregate into four scales assessing future uncertainty, visual disorder, motor dysfunction, and communication deficit. The remaining single items assess other disease symptoms (e.g. headaches and seizures) and treatment toxic effects (e.g. hair loss). Raw scores items were computed and subsequently transformed linearly to a 0-100 scale. A higher score represents worse quality of life. |
| Progression-free Survival | up to 4 years | Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) or death due to any cause. PD is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1: \- PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD. |
| Central Nervous System Objective Response Rate | Up to 4 years | Objective response rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response: * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. |
| Central Nervous System Progression-free Survival | up to 4 years | Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) in the central nervous system (CNS) or death due to CNS disease. PD is evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response: \* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days). | 6 |
| Phase II: RP2D In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion. | 5 |
| Total | 11 |
Baseline characteristics
| Characteristic | Phase II: RP2D | Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Total |
|---|---|---|---|
| Age, Continuous | 50 years | 42 years | 46 years |
| Brain metastases Absent | 0 Participants | 2 Participants | 2 Participants |
| Brain metastases Present | 5 Participants | 4 Participants | 9 Participants |
| Eastern Cooperative Oncology Group (ECOG) performance status Score 0 | 3 Participants | 4 Participants | 7 Participants |
| Eastern Cooperative Oncology Group (ECOG) performance status Score 1 | 2 Participants | 1 Participants | 3 Participants |
| Eastern Cooperative Oncology Group (ECOG) performance status Score 2 | 0 Participants | 1 Participants | 1 Participants |
| Prior anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy No | 2 Participants | 4 Participants | 6 Participants |
| Prior anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy Yes | 3 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 5 Participants | 3 Participants | 8 Participants |
| Sex: Female, Male Female | 4 Participants | 2 Participants | 6 Participants |
| Sex: Female, Male Male | 1 Participants | 4 Participants | 5 Participants |
| Smoking status Light (less than 10 pack-years) | 2 Participants | 1 Participants | 3 Participants |
| Smoking status Never | 3 Participants | 5 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 6 | 3 / 5 |
| other Total, other adverse events | 6 / 6 | 5 / 5 |
| serious Total, serious adverse events | 1 / 6 | 2 / 5 |
Outcome results
Primary
(Phase 1) Recommended Phase II Dose of Alectinib
The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose. Dose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs.
Time frame: first cycle of treatment (21 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | (Phase 1) Recommended Phase II Dose of Alectinib | 600 mg |
Primary
(Phase 1) Recommended Phase II Dose of Bevacizumab
The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose. Dose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs.
Time frame: first cycle of treatment (21 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | (Phase 1) Recommended Phase II Dose of Bevacizumab | 15 mg/kg |
Primary
(Phase 2) Number of Participants With Intracranial Hemorrhagic Events Who Received RP2D
In the phase II portion of the study, we aim to further investigate the safety and tolerability of alectinib plus bevacizumab at the RP2Ds as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The combination of alectinib and bevacizumab will be deemed unsafe if 2 or more participants are observed to have grade 2 or higher, central nervous system (CNS) intracranial hemorrhagic events.
Time frame: up to 4 years
Population: RP2Ds for alectinib plus bevacizumab were confirmed in August 2016. Enrollment for the phase II cohort occurred from August 2016 to February 2020. We initially planned to enroll 20 participants to the phase II cohort but due to slow accrual, the decision was made to stop the study prematurely in July 2021.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | (Phase 2) Number of Participants With Intracranial Hemorrhagic Events Who Received RP2D | 0 participants |
Secondary
Central Nervous System Disease Control Rate
Disease control rate (DCR) is the percentage of participants with intracranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response: * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. * SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters. * PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.
Time frame: Up to 4 years
Population: One participant from the phase 1 cohort was excluded from analysis because they didn't have an intracranial lesion(s) at enrollment, nor did they develop any while on study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Central Nervous System Disease Control Rate | 100 percentage of participants |
| Phase II: RP2D | Central Nervous System Disease Control Rate | 100 percentage of participants |
Secondary
Central Nervous System Objective Response Rate
Objective response rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response: * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 4 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Central Nervous System Objective Response Rate | 66.66 percentage of participants |
| Phase II: RP2D | Central Nervous System Objective Response Rate | 60.00 percentage of participants |
Secondary
Central Nervous System Progression-free Survival
Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) in the central nervous system (CNS) or death due to CNS disease. PD is evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response: \* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.
Time frame: up to 4 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Central Nervous System Progression-free Survival | 23.87 months |
| Phase II: RP2D | Central Nervous System Progression-free Survival | 7.21 months |
Secondary
Health-related Quality of Life Questionnaire EORTC QLQ-C30
The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of functional scales, symptom scales, a global health status/quality of life (QOL) scale. All of the scales range in score from 0 to 100. A summary score is calculated as the average of all scores. High score for functional scales mean high level of functioning. High score for global health status means high quality of life. High score for symptom scales mean high level of problems.
Time frame: Baseline to cycle 7 (21 weeks)
Population: Only participants who completed the baseline questionnaire and C7D1 post-treatment questionnaire will be included in the analysis.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline: Functional scales | 86.67 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Cycle7: Functional scales | 87.78 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline: Symptom scales | 15.38 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Cycle7: Symptom scales | 12.83 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline: Global health status/QOL | 75.00 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Cycle7: Global health status/QOL | 58.33 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline: Global health status/QOL | 25.00 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline: Functional scales | 42.22 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Cycle7: Symptom scales | 30.77 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Cycle7: Functional scales | 68.89 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Cycle7: Global health status/QOL | 75.00 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire EORTC QLQ-C30 | Baseline: Symptom scales | 38.46 score on a scale |
Secondary
Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20
The European Organization for Research and Treatment of Cancer quality of life questionnaire has a brain cancer nodule (EORTC QLQ-BN20) developed for patients undergoing chemotherapy or radiotherapy. It includes 20 items, 13 of which aggregate into four scales assessing future uncertainty, visual disorder, motor dysfunction, and communication deficit. The remaining single items assess other disease symptoms (e.g. headaches and seizures) and treatment toxic effects (e.g. hair loss). Raw scores items were computed and subsequently transformed linearly to a 0-100 scale. A higher score represents worse quality of life.
Time frame: Baseline, Cycle 7 Day 1 (21 weeks)
Population: Only participants who completed the baseline questionnaire and C7D1 questionnaire will be included in the analysis.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Motor dysfunction | 0.00 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Visual disorder | 7.41 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Communication deficit | 0.00 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Future uncertainty | 16.67 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Communication deficit | 0.00 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Visual disorder | 0.00 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: other symptoms | 9.52 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Future uncertainty | 38.89 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: other symptoms | 15.87 score on a scale |
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Motor dysfunction | 0.00 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: other symptoms | 19.05 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Future uncertainty | 58.33 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Future uncertainty | 33.33 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Visual disorder | 0.00 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Visual disorder | 0.00 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Motor dysfunction | 11.11 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Communication deficit | 77.78 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Cycle7: Communication deficit | 100.00 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: other symptoms | 19.05 score on a scale |
| Phase II: RP2D | Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20 | Baseline: Motor dysfunction | 22.22 score on a scale |
Secondary
Overall Disease Control Rate
Disease control rate (DCR) is the percentage of participants with intra- and extra-cranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1: * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. * SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters. * PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.
Time frame: Up to 4 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Overall Disease Control Rate | 100 percentage of participants |
| Phase II: RP2D | Overall Disease Control Rate | 100 percentage of participants |
Secondary
Overall Objective Response Rate
Objective response rate (ORR) is defined as the percentage of participants with intra- and extra-cranial complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. * CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm. * PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 4 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Overall Objective Response Rate | 83.33 percentage of participants |
| Phase II: RP2D | Overall Objective Response Rate | 60.00 percentage of participants |
Secondary
Progression-free Survival
Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) or death due to any cause. PD is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1: \- PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.
Time frame: up to 4 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg | Progression-free Survival | 23.64 months |
| Phase II: RP2D | Progression-free Survival | 4.95 months |